Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone49-3818-011-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$47.81 million
Profitability
Miscellaneous
Employees400
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable
Centogene (NASDAQ:CNTG) Frequently Asked Questions
What is Centogene's stock symbol?
Centogene trades on the NASDAQ under the ticker symbol "CNTG."
When is Centogene's next earnings date?
What price target have analysts set for CNTG?
4 brokers have issued twelve-month price targets for Centogene's stock. Their forecasts range from $15.00 to $18.00. On average, they expect Centogene's stock price to reach $16.67 in the next year. This suggests a possible upside of 47.8% from the stock's current price. View Analyst Price Targets for Centogene.
What is the consensus analysts' recommendation for Centogene?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Centogene in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Centogene.
Has Centogene been receiving favorable news coverage?
Headlines about CNTG stock have been trending neutral on Friday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Centogene earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Centogene.
Who are some of Centogene's key competitors?
Some companies that are related to Centogene include Castle Biosciences (CSTL), Personalis (PSNL), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Cancer Genetics (CGIX), Avant Diagnostics (AVDX), CBA Florida (CBAI), OpGen (OPGN), Biocept (BIOC) and First Choice Healthcare Solutions (FCHS).
What other stocks do shareholders of Centogene own?
Who are Centogene's key executives?
Centogene's management team includes the folowing people:
- Prof. Arndt Rolfs, CEO, Chief Medical Officer & Member of Management Board (Age 60)
- Mr. Richard Stoffelen, CFO & Member of Management Board (Age 52)
- Dr. Dirk H. Ehlers, COO, Pres of Clinical Diagnostics & Member of Management Board (Age 58)
- Dr. Volkmar Weckesser Ph.D., Chief Information Officer & Member of Management Board (Age 52)
- Prof. Peter Bauer M.D., Chief Scientific Officer (Age 50)
When did Centogene IPO?
(CNTG) raised $60 million in an initial public offering on Thursday, November 7th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. SVB Leerink and Evercore ISI acted as the underwriters for the IPO and Baird and BTIG were co-managers.
When does the company's quiet period expire?
Centogene's quiet period expires on Tuesday, December 17th. Centogene had issued 4,000,000 shares in its IPO on November 7th. The total size of the offering was $56,000,000 based on an initial share price of $14.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
How do I buy shares of Centogene?
Shares of CNTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Centogene's stock price today?
One share of CNTG stock can currently be purchased for approximately $11.28.
How big of a company is Centogene?
What is Centogene's official website?
How can I contact Centogene?
Centogene's mailing address is AM STRANDE 7, ROSTOCK 2M, 18055. The company can be reached via phone at 49-3818-011-3400 or via email at [email protected]
MarketBeat Community Rating for Centogene (NASDAQ CNTG)
MarketBeat's community ratings are surveys of what our community members think about Centogene and other stocks. Vote "Outperform" if you believe CNTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
